ClinicalTrials.Veeva

Menu

CaMaPi for Adolescents/Young People With a History of Self-harm and Suicidal Ideation in Jos, Nigeria

N

Nottingham Trent University

Status

Not yet enrolling

Conditions

Suicidal Ideation
Self-harm

Treatments

Other: TAU
Behavioral: CaMaPi

Study type

Interventional

Funder types

Other

Identifiers

NCT06440031
0000-0001-5034-0335f

Details and patient eligibility

About

Suicide and self-harm are global disease burden that contributes significantly to years of lost life and mortality.

Full description

Self-harm and suicidal ideation represent a significant global public health concern (Knipe et al., 2022), affecting about 14.6 million people yearly (Nichols et al., 2021). Globally, over 700 000 people die by suicide annually (World Health Organization -- WHO, 2023).

Suicide is the fourth leading cause of death among 15-29-year-olds, and 77% of global suicides occur in low- and middle-income countries, including Nigeria (WHO, 2023). The psychological impact of suicidal ideation includes continuing high tendencies of self-harm (Jidong et al., 2024).

Despite the increasing rates of suicide and self-harm in Nigeria, this topic is understudied, with no culturally appropriate or sustainable psychological interventions.

Enrollment

32 estimated patients

Sex

All

Ages

16 to 24 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients aged 16-24 years presenting to the participating services, and emergency departments or admitted after an episode of self-harm to the participating hospitals or self-referrals.
  • Participants will have to be living within the catchment area of the participating practices, services and hospitals.
  • Not needing inpatient psychiatric treatment.

Exclusion criteria

  • Severe mental illness (such as Psychotic disorder).
  • Conditions limiting engagement with assessment/intervention.
  • Temporary resident unlikely to be available for follow up.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

32 participants in 2 patient groups

CaMaPi
Experimental group
Treatment:
Behavioral: CaMaPi
TAU
Active Comparator group
Treatment:
Other: TAU

Trial contacts and locations

0

Loading...

Central trial contact

Dung Jidong, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems